The anti-tumor activity of sorafenib was attributed to its inhibition of angiogenesis (VEGFR and PDGFR) and direct effect on tumor cell proliferation and survival (RAF/MEK/ERK pathway) (23). Here, MAP2K7 is linked to neoplasm.